{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Partial response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.\n\nTRANSPLANT: Patients undergo autologous PBSCT on day 0.\n\nBusulfan: Given IV\n\nMelphalan: Given IV\n\nBortezomib: Given IV\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT\n\nPeripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT","id":"OG000","title":"Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to day 100","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}